A new approach in clinical trials: “virtual twin” technology

A new approach in clinical trials: “virtual twin” technology

The article “Twin ambitions”, published in PharmaTimes magazine, highlights the importance of clinical trial digitalisation and “virtual twin” technologies in the pharmaceutical industry.

In the pharmaceutical industry, a single poorly designed clinical trial can cost companies hundreds of millions, years of development time, or in some cases, prevent a new treatment from ever reaching patients.

“Virtual twin” technology helps prevent such avoidable failures. This approach allows sponsors to test, refine, and optimise trial designs before the clinical trial begins. As a result, risks are reduced, timelines are accelerated, and new opportunities for innovation are created across the pharmaceutical ecosystem.

The concept of a “virtual twin” is rooted in product life cycle management, which was historically used to design complex products such as aircraft. Today, this technology is becoming an important tool for improving the efficiency of clinical trials, supporting better decision-making, and advancing the development of new medicinal products.

This approach once again demonstrates the growing importance of digital transformation, clinical trial quality, and innovative solutions in the pharmaceutical sector.